Axon Research Foundation
We make psychedelic-assisted therapy
possible in Scandinavia.
We bridge the gap between research and treatment so that more people can access therapy that works.
Learn about what we doIn partnership with
About the foundation
Research, treatment and dissemination
Axon Research Foundation funds and conducts research on the use of psychedelics for the treatment of mental health conditions. We offer pro bono treatment, publish research findings and educate professionals in the medical use of psychedelics.
The foundation is independent, non-profit and Norway-based. We have four pillars: research, treatment, dissemination and the measures needed to make responsible use possible in Norway.
Support Project Momentum
Help us fund treatment for the first 10 veterans
The foundation has no commercial interests. All donations are earmarked for Project Momentum. Every contribution brings us closer to treating 10 veterans and research that can influence Norwegian mental health policy.
Fundraising goal
0kr
12% funded
Treatment
4 ketamine sessions per veteran, 10 veterans
Research
Psychometric data collection, analysis, study coordination
Publication
Peer review, open access, reporting to health authorities
In partnership with
The people behind Axon
Axon Research Foundation was founded by Nils Furusund to promote psychedelic-assisted therapy through research, treatment and education.
I started Axon because I saw too many patients fall through the cracks in conventional treatment. Psychedelic-assisted therapy can reach them.
Nils Furusund,Founder and Chairman
Our mission is to build the infrastructure for responsible psychedelic therapy in Norway. Research, treatment and education, all under one roof.
Ida Falchenberg,CEO
The clinical evidence is strong. What we need now is the courage to act and the structures to do it safely.
Lowan Stewart,Board Member, Clinical Director
Mental health treatment in Norway needs new alternatives. We are here to create them, grounded in research and clinical responsibility.
Sissel Leire,Board Member
Every treatment we fund also generates data. That is how we turn individual results into systemic change.
Anniken Fjellberg,Board Member
Our approach
Patience and action
Psychedelic-assisted therapy is a rapidly evolving field. We combine scientific rigor with a willingness to act. Those who need treatment cannot wait for the system to catch up with the research.
For veterans
PTSD can be treated. Current alternatives are not enough. We are building something better.
For donors
You fund concrete treatment and research. Every contribution goes directly to the project.
For institutions and foundations
We are building infrastructure for psychedelic-assisted therapy in Norway. From clinic to regulatory framework.
Our mission
What we do
The foundation works on research, treatment, dissemination and policy. Responsible use of psychedelics requires more than clinical results alone.
Research
We fund and conduct clinical research on psychedelic-assisted therapy for mental health conditions.
Treatment
Pro bono treatment for patients where current alternatives fall short. Safe settings, protocols, follow-up.
Dissemination
Publication of research results, training of professionals and public education about the medical use of psychedelics.
Projects
Our projects
Norwegian veterans with treatment-resistant PTSD have few options left. We are building two projects to change that — one treating patients now, the other generating the research needed to change the system.
Project Momentum
KAP treatment for 10 veterans with PTSD
Our first project. 10 veterans receive ketamine-assisted psychotherapy at Axon Clinic — 4 sessions each, with structured follow-up at 3, 6, and 12 months. Every treatment also produces data for peer-reviewed publication. Launching spring 2026.
Read more about Project Momentum
Project Nighthawk
Psilocybin treatment in groups for 24 veterans with PTSD
The first clinical psilocybin trial for veterans in Norway. 24 participants in 6 cohorts receive group-based psychedelic-assisted therapy over 8 weeks. Designed to test whether shared veteran experience strengthens therapeutic outcomes. Planned for 2027–2028.
Read more about Project Nighthawk